版本:
中国

BRIEF-Halozyme provides update on Abbvie collaboration

Nov 21 Halozyme Therapeutics Inc :

* Halozyme Therapeutics Inc - abbvie has discontinued a development program using halozyme enhanze platform technology

* Halozyme - co, abbvie will continue to work to identify additional targets for co-development under 2015 global collaboration,licensing agreement

* Halozyme Therapeutics - abbvie has discontinued development program following completion of a phase 1 study in which target results were not achieved

* Halozyme Therapeutics-abbvie discontinued development program using halozyme enhanze platform technology, tnf-alpha target after completion of phase 1 study

* Halozyme provides update on abbvie collaboration Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐